ClinicalTrials.gg

Program

FWY003

A development code.

In Novartis's pipeline, Factor B inhibitor. Its studies are mostly in Geographic Atrophy, led by Novartis.

Furthest: phase 2, since Feb 24, 20261 company-led study, 1 open or runningNext primary completion: Aug 21, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis11 open or runningphase 2since Feb 24, 2026Feb 24, 2026Aug 21, 2029phase 2 · NCT07441642
  • Named in Novartis’s own pipeline as FWY003, phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 24, 2026First study: phase 2 study in Geographic Atrophy Secondary to Age-related Macular DegenerationFirst studyNCT07441642 · 272 planned · United States, Argentina, Australia and more

Ahead

  1. Aug 21, 2029Primary completion: phase 2 study in Geographic Atrophy Secondary to Age-related Macular DegenerationNCT07441642

TargetBeta

“Factor B inhibitor”the company's pipeline, read by Claude · source

Other programs on CFB

ProgramCompanyFurthest phaseStudies
iptacopanruleNovartisphase 325
HRS-5965Jiangsu HengRui Medicinephase 314
NTQ5082ruleSino Biopharmaceuticalphase 36
FXS6837Fosun Pharmaphase 34
sefaxersenHoffmann-La Rochephase 31
HS-10542Hansoh Pharmaceutical Groupphase 23
SAR446597Sanofiphase 21

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07441642Geographic Atrophy Secondary to Age-related Macular Degeneration · United States, Argentina, Australia and more2RecruitingAug 21, 2029272

How it is read

Names in the registry

  • “FWY003”, 1 entry

Codes read as this program: FWY003.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.